Announcements Trials
Browse Landscape

Phase

Phase 1 7Phase 2 2Phase 1/2 2Phase 3 1

Status

Completed 2Unknown 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Other hematologic neoplasm 1Myeloid 1

Conditions

Small Cell Lung Carcinoma 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Lung Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid, Acute 1Leukemia 1Congenital Abnormalities 1

Interventions

Cyclophosphamide 739Cisplatin 687Gemcitabine 641Bevacizumab 615Carboplatin 604Paclitaxel 600Docetaxel 565Radiotherapy 536Fluorouracil 405Oxaliplatin 387Rituximab 369Doxorubicin 360Capecitabine 342Filgrastim 333Etoposide 328Dexamethasone 312Irinotecan 309pembrolizumab 279Leucovorin 274Cetuximab 267Cytarabine 242Erlotinib Hydrochloride 231Prednisone 227Nivolumab 227Trastuzumab 225Bortezomib 221Vincristine 220Methotrexate 207Pemetrexed 199fludarabine phosphate 195

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Completed × laromustine × Clear all
NCT00282022 2013-11-06

VNP40101M in Treating Patients With Relapsed or Refractory Locally Advanced or Metastatic Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 2 Completed
87 enrolled
Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

NCT00083187 2013-07-18

VNP40101M in Treating Patients With Acute Myelogenous Leukemia or High-Risk Myelodysplasia

National Cancer Institute (NCI)

Phase 2 Completed
230 enrolled
MyeloidOther hematologic neoplasm

Congenital Abnormalities, Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

Data powered by HemOnc (CC BY 4.0) Colophon âš¡